Acquisition targets risk management

United BioSource Corp. has acquired drug safety software maker Gigamoto Technology Partners. The acquisition, says UBC, is part of a strategy to build integrated capabilities in risk management and drug safety.

UBC's global drug safety and risk management services include risk evaluation and mitigation programs. Gigamoto--UBC's second purchase this year in support of its objective to expand globally--provides additional scale and commercial Internet site functionality to UBC's offerings, according to an announcement.

The Gigamoto software powers several complex risk management programs, including the FDA-mandated iPLEDGE program. iPLEDGE is a computer-based distribution center that monitors pregnancy in women taking the acne medication Accutane, (isotretinoin), known to cause birth defects. iPLEDGE was mandated by the FDA in 2006. The risk-management system has registered more than 40,000 pharmacies, 16,000 prescribers and 300,000 patients.

- read the announcement

Suggested Articles

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

Elligo Health Research will test a harmonized real-word data model built by the FDA.

Just about a year after filing its IPO application BGI hits a big wall with a regulatory review.